A phase 1 study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody administered subcutaneously in subjects with plaque psoriasis - 21/08/11
Alice Gottlieb, MD, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick, NJ, United States; Bart Frederick, BS, Centocor, Inc., Malvern, PA, United States; Dan Everitt, MD, Tom McCormick, PhD, Case Western Reserve University, Cleveland, OH, United States
Le texte complet de cet article est disponible en PDF. P2705 Dr. Gottlieb is a consultant, investigator, and ad board member for Centocor. Dr. McCormick has no significant financial interest in Centocor. Support for the phase 1 study provided by Centocor |
Vol 52 - N° 3S
P. P172 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?